RxDoctor Payments Data

Debra Scarlett, MD

Dermatology · Milwaukee, WINPI 1700802923

Payments from drug & device makers

$1,985in general payments, 2019–2025

Across 87 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$460
  • AbbVie$275
  • Sanofi-aventis U.S. LLC$162
  • Novartis$157
  • Sanofi$155
  • LEO Pharma Inc.$133
  • plus $643 from 12 others

What the payments were for

  • Food & beverage$1,59080%
  • Education$39420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,985 in reported general payments places this provider in the 75th percentile of 260 dermatology providers in Wisconsin.

See all dermatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$149,022
Medicare patients
782
Services billed
2,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab43$184,423
RinvoqUpadacitinib23$154,811
OtezlaApremilast27$131,265
Fluorouracil277$20,248
Betamethasone Dipropionate172$6,493
Ketoconazole199$4,318
Clobetasol Propionate108$3,831
Pimecrolimus20$3,362
Minocycline Hcl109$2,429
Metronidazole38$2,192
MethotrexateMethotrexate Sodium75$1,744
Triamcinolone Acetonide185$1,669
Tretinoin13$1,200
Finasteride91$1,031
ValacyclovirValacyclovir Hcl28$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$275$154,81123 claims
AmgenOtezla$100$131,26527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 260 dermatology providers in Wisconsin.

Other dermatology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →